The Cancer SNP Panel delivers high-quality data and provides an efficient, cost-effective tool for conducting candidate-gene based association studies in cancer. Such studies using targeted SNPs are faster and more cost-effective than alternative approaches that may require complete re-sequencing of candidate genes or larger studies that require whole genome genotyping panels.

This Panel consists of 1,421 thoroughly screened and validated SNP loci from > 400 genes thought to be involved in cancer. Panel content was selected from the National Cancer Institute's Cancer Genome Anatomy Project SNP500 Cancer Database.

SNPs in the panel were chosen to be within 10kb of each gene and to represent several pathways thought to be involved in the etiology of various types of cancers including apoptosis, oncogenesis, tumor suppression, and G-protein coupled receptor protein signaling. The distribution of SNPs by gene region includes > 300 coding SNPs of which 158 cause amino acid changes in the resulting protein. In the Cancer SNP Panel, > 3 SNP assays were selected, on average, for each gene represented.

The SNP assays included on the Cancer SNP Panel were subjected to rigorous functional testing to ensure strong performance and suitability for association studies using Illumina's GoldenGate Assay. To determine call rate, reproducibility, and Mendelian inconsistencies, three populations were studied: Caucasians, Han Chinese and Japanese, and Yoruba Africans. Genotype concordance was assessed by comparing loci in the Illumina Cancer SNP Panel to genotype data from the SNP500 Cancer Database.

• SNP sequences are optimized for Illumina's proven GoldenGate Genotyping Assay protocol

• The Cancer SNP Panel can be deployed on 12-sample and 32-sample Universal BeadChips.

Catalog IDs: GT-17-211